Tango Therapeutics Investor Relations Material

Tango Therapeutics Inc. is a biotechnology firm focused on the discovery and development of innovative treatments for cancer. The company's research is centered on creating drugs that target specific genetic vulnerabilities in cancer cells. One of its leading projects, TNG908, is a synthetic lethal small molecule inhibitor designed for treating cancers characterized by methylthioadenosine phosphorylase deletions. Additionally, Tango Therapeutics is developing several other compounds, including TNG462 for similar indications, TNG260 targeting repressor element-1 silencing transcription, TNG348 aimed at BRCA1 or BRCA2-mutant cancers, and another compound targeting STK11-mutant cancers. The company is based in Boston, Massachusetts and its shares are listed on the Nasdaq.